This is what makes me question their motives. You have a promising treatment that can be available to everyone, but you choose not to share any details because of "regulations". I mean, if you don't care for the financial aspects, you don't care for the regulations/patent filing either, but instead focus on sharing knowledge and experience.
From what I've read from their answers on facebook and articles, I suspect that their interest in contacting other researchers is for their own self interests, not the patients. For instance, when asked if they've contacted fluge/mella after their article on the PDH enzyme, their answer is that fluge/mella should contact them because they discovered the link to pdh earlier. And since they didn't want to share any details at all with the Norwegian cfs association, I'm not so sure they will share spesifics with other researchers.
I don't get their approach to this at all. If it's financial motives keeping them from sharing, they should do the opposite since they control the patent. They should share knowledge and experience. And then they can develop a more convenient and perhaps effective treatment through a patent protected drug, than todays somewhat inconvinient alternative of making a fresh blend each day four times a day.
@JES Maybe someone with a more relevant background similar to Bohne can piece together the puzzle...
@Frenchguy Do not even the patients getting the treatment know the ingredients?